MTVA

MetaVia Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001638287 Biotech & Drug Discovery

$1.22 −0.16 (−11.96%)

Oct 26 4:00 PM ET · prev $1.38

Market cap

$9.2M

Nano cap

Median target

$20.00

+1546% · range $8.00–30.00

Next earnings

Nov 16

in 20 days · EPS est. −$0.73

1 year

−88.6%

from $10.64 · Oct 27

30 days

−27.2%

from $1.67

52-week range

$0.9700–11.88

−90% from high · low May 12

Avg volume 20D

64.3K

shares / day

Short interest

🔒 Subscribers only

Insider net

no open-market trades · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 3 reports · 90 days

Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score

Avg score

·High conf. 2/3 ·Next Earnings date, Nov 16, 2026

Strongest NEUTRAL MetaVia Inc. appointed Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective October 12, 2026. Dr…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R May 27 MetaVia Inc. (MTVA) disclosed Phase 1 data for DA-1726 at EASL 2026.…
R Jun 8 MetaVia Inc. held its 2026 annual meeting on June 8, 2026, with stoc…
R Jun 8 MetaVia presented new late-breaking Phase 1 data for DA-1726 (48 mg…
R Jul 2 MetaVia Inc. filed a 424B5 prospectus supplement to increase its ATM…
X Jul 31 Short interest falls 53.4% to 160.5K
X Aug 14 Short interest jumps 31.7% to 211.3K
X Sep 30 Short interest falls 36.0% to 117.4K

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
InstitutionsMIXED

Q2 2026: 3 added (0 new), 2 trimmed or exited.
EstimatesFLAT

Current-quarter EPS estimate −$0.747 → −$0.733 over 90 days. 1 up, 0 down in 30 days.
TrendDOWNTREND

22% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
JANE STREET GROUP, LLC	DOUBLED	123,583	$176.7K
GEODE CAPITAL MANAGEMENT, LLC	TRIM	21,314	$30.5K
UBS Group AG	DOUBLED	12,948	$18.5K
VANGUARD CAPITAL MANAGEMENT LLC	DOUBLED	8,919	$12.8K
BlackRock, Inc.	NEAR_EXIT	7	$10.00
UBS Group AG	NEAR_EXIT	1	$1.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026

12-month targets · 3 analysts

$1.22 $8.00 $20.00 $30.00

Price is below the lowest target. Median implies +1546%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Jul 10, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
May 18, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
Oct 12, 2026	Browne Sarah Kaplan Chief Medical Officer	AWARD	53,000 sh
Jun 8, 2026	Glickman Mark A Director	AWARD	17,186 sh
Jun 8, 2026	KOVEN ANDREW I Director	AWARD	17,186 sh
Jun 8, 2026	GROVES JASON L Director	AWARD	17,186 sh
Jun 8, 2026	Salsbury Michael Director	AWARD	17,186 sh
Jun 8, 2026	STRICKLAND D GORDON Director	AWARD	17,186 sh
Jun 8, 2026	Tursi James Patrick Director	AWARD	17,186 sh

Earnings setup

Estimates

Nov 16

reports in 20 days

−$0.73

EPS estimate, this quarter

+2%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.747

90d

−$0.747

60d

−$0.737

30d

−$0.733

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.73	-$0.94–-$0.33	+0.5%	$0.00
Next Q	-$0.75	-$0.98–-$0.35	+0.4%	$0.00
Current FY	-$2.52	-$3.61–-$1.97	+30.3%	$0.00
Next FY	-$2.37	-$4.51–-$1.07	+0.1%	$0.00